NEWS 

Real-time and near-time news

 

 

 

ANALYSIS

Stock analysis as news feed

 

 

VIDEO

Range of services

 

 

Newsticker

Companies
Economic News
Markets

PolarityTE: FDA Grants RMAT Designation For SkinTE

|   Companies

 

WASHINGTON (dpa-AFX) - PolarityTE, Inc. (PTE) announced the FDA granted a Regenerative Medicine Advanced Therapy designation to SkinTE. RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products.

Richard Hague, CEO, said: 'The Agency has offered-and we look forward to capitalizing upon-a multidisciplinary, comprehensive discussion between PolarityTE and the FDA regarding the SkinTE development program, including planned clinical trials and plans for expediting the manufacturing development strategy.'

Shares of PolarityTE were up 92% in pre-market trade on Friday.

Copyright(c) 2022 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

PolarityTE: FDA Grants RMAT Designation For SkinTE

|   Companies

 

WASHINGTON (dpa-AFX) - PolarityTE, Inc. (PTE) announced the FDA granted a Regenerative Medicine Advanced Therapy designation to SkinTE. RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products.

Richard Hague, CEO, said: 'The Agency has offered-and we look forward to capitalizing upon-a multidisciplinary, comprehensive discussion between PolarityTE and the FDA regarding the SkinTE development program, including planned clinical trials and plans for expediting the manufacturing development strategy.'

Shares of PolarityTE were up 92% in pre-market trade on Friday.

Copyright(c) 2022 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

PolarityTE: FDA Grants RMAT Designation For SkinTE

|   Companies

 

WASHINGTON (dpa-AFX) - PolarityTE, Inc. (PTE) announced the FDA granted a Regenerative Medicine Advanced Therapy designation to SkinTE. RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products.

Richard Hague, CEO, said: 'The Agency has offered-and we look forward to capitalizing upon-a multidisciplinary, comprehensive discussion between PolarityTE and the FDA regarding the SkinTE development program, including planned clinical trials and plans for expediting the manufacturing development strategy.'

Shares of PolarityTE were up 92% in pre-market trade on Friday.

Copyright(c) 2022 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

nach oben